Released Feb 23, 2017, after the close
10-K filed Feb 23, 2017, 54 days after period end · 0000917520-17-000010
Q4 2016 · 10-K
Revenue$255.66M$255.66M +6.0% vs Q4 2015+2.1% vs Q3 2016
Net Income$28.25M$28.25M +88.6% vs Q4 2015+40.2% vs Q3 2016
EPS Diluted$0.35$0.35 +75.0% vs Q4 2015+40.0% vs Q3 2016
Gross Profit$170,242,000+12.6%
Operating Incomederived$40,768,000+69.8%
Operating Cash Flowderived$6,529,000−74.5%
Free Cash Flowderived-$14,663,000N/M
Margins · derived
Gross margin66.6%+3.9 pt vs Q4 2015
Operating margin15.9%+6.0 pt vs Q4 2015
Net margin11.0%+4.8 pt vs Q4 2015
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2016 | Q4 2015 | Q4 2014 | Q4 2013 |
|---|---|---|---|---|
| Revenue | $255.66M | $241.16M | $219.07M | $220.77M |
| Net Income | $28.25M | $14.98M | $17.17M | $13.77M |
| EPS Diluted | $0.35 | $0.20 | $0.52 | $0.45 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Integra Lifesciences Holdings Corp · CIK 917520 · Engraved from SEC EDGAR